Corium International, Inc. (NASDAQ:CORI) major shareholder Healthcare Master Fun Broadfin sold 218,100 shares of the company’s stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $11.01, for a total transaction of $2,401,281.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Corium International, Inc. (NASDAQ:CORI) traded up 0.54% during midday trading on Friday, hitting $11.10. 120,958 shares of the stock traded hands. The firm’s market cap is $396.74 million. Corium International, Inc. has a 1-year low of $2.67 and a 1-year high of $11.37. The company has a 50-day moving average price of $9.54 and a 200-day moving average price of $7.24.

Corium International (NASDAQ:CORI) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.13). The business had revenue of $8.11 million during the quarter, compared to analyst estimates of $8.71 million. Corium International had a negative net margin of 145.60% and a negative return on equity of 673.17%. Analysts predict that Corium International, Inc. will post ($1.70) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/06/healthcare-master-fun-broadfin-sells-218100-shares-of-corium-international-inc-cori-stock.html.

Several equities analysts recently commented on the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $10.00 price target (up previously from $8.00) on shares of Corium International in a research report on Monday, August 7th. Zacks Investment Research raised shares of Corium International from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Tuesday. ValuEngine raised shares of Corium International from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub lowered shares of Corium International from a “buy” rating to a “hold” rating in a research report on Thursday, August 3rd. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $12.00 price target on shares of Corium International in a research report on Wednesday, September 27th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Corium International currently has an average rating of “Buy” and a consensus price target of $13.00.

A number of hedge funds and other institutional investors have recently bought and sold shares of CORI. Bank of New York Mellon Corp lifted its stake in Corium International by 118.1% in the first quarter. Bank of New York Mellon Corp now owns 25,269 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 13,683 shares during the last quarter. New York State Common Retirement Fund acquired a new stake in Corium International in the second quarter valued at approximately $158,000. California State Teachers Retirement System acquired a new stake in Corium International in the second quarter valued at approximately $263,000. Teachers Advisors LLC acquired a new stake in Corium International in the second quarter valued at approximately $272,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in Corium International in the second quarter valued at approximately $411,000. Hedge funds and other institutional investors own 90.14% of the company’s stock.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Insider Buying and Selling by Quarter for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.